Phenotypic and functional heterogeneity arise among cancer cells within the same tumour
as a consequence of genetic change, environmental differences and reversible changes in …

T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% and 25% of total childhood
and adult ALL cases, respectively. During T-ALL, patients are at risk of organ infiltration by …

Most cancers evolve over time as patients initially responsive to therapy acquire resistance
to the same drugs at relapse. Cancer stem cells have been postulated to represent a therapy …

Tumor relapse is associated with dismal prognosis, but responsible biological principles
remain incompletely understood. To isolate and characterize relapse-inducing cells, we …

Disease recurrence causes significant mortality in B-progenitor acute lymphoblastic
leukemia (B-ALL). Genomic analysis of matched diagnosis and relapse samples shows …

Relapse after autologous or allogeneic hematopoietic stem cell transplantation has become
the most frequent cause of treatment failure. The third International Workshop on Biology …

Xenotransplantation of patient-derived samples in mouse models has been instrumental in
depicting the role of hematopoietic stem and progenitor cells in the establishment as well as …

Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic
hematopoietic cell transplantation, result in an overall survival of approximately 40%, a …

Intensive multi‐agent chemotherapy regimens and the introduction of risk‐stratified therapy
have substantially improved cure rates for children with acute lymphoblastic leukaemia …

Chromosomal translocations that generate oncogenic fusion proteins are causative for most
pediatric leukemias and frequently affect the MLL/KMT2A gene. In vivo modeling of bona …